GentleGen completes nearly RMB 100M Series A, leading the automation revolution in gene technology

GentleGen, a leading player in the new generation of automated and intelligent gene technology applications, announced the completion of an approximately 100 million Series A financing round. This round was jointly led by Tenykin Capital, Jinqiao Fund, and Jinhai VC, with participation from Optics Valley Industrial Investment. WinX Capital acted as the exclusive financial advisor.

The raised funds will be primarily allocated to the enhancement and upgrade of fully automated production lines, the iteration of core technologies, team expansion, and global market expansion. These strategic investments aim to further advance the global deployment of automated gene technology applications.

As a pioneer in China that has achieved end-to-end automated and scalable application, GentleGen focuses on the integration of "automation + intelligence" and has established a comprehensive, one-stop automated gene technology application platform. This platform covers gene sequencing, synthesis, editing, and expression, providing customers in fields such as synthetic biology and biopharmaceuticals with automated solutions ranging from single-scenario applications to integrated one-stop services.

GentleGen is committed to fundamental technological innovation, continuously breaking through industry bottlenecks. The company has independently developed the world's first fully automated Sanger sequencing production line, an oligonucleotide synthesis automation line, and a high-throughput gene synthesis automation line. These systems operate 24/7, achieving production efficiency and success rates far surpassing traditional manual service models. This technological strength places GentleGen at the forefront globally and provides pioneering industry practice for establishing "smart, lights-out factories" in the gene technology application field. Furthermore, its intelligent automated gene synthesis and sequencing production lines serve as critical infrastructure enabling the "AI + Life Sciences" strategy, ensuring its effective implementation.

Additionally, GentleGen continues to invest in the research and development of next-generation innovative gene synthesis technologies, small nucleic acid and conjugate technologies, as well as the NGSafety® platform for quality analysis, safety testing, and evaluation in next-generation cell and gene therapies. These efforts provide specialized solutions for synthetic biology and biopharmaceutical R&D.

Leveraging its top-tier core team, GentleGen has rapidly achieved commercialization. Core team members possess an average of over ten years of comprehensive experience across the entire gene technology workflow and demonstrate highly efficient collaboration. GentleGen has established a high-performance operational model driven by both "biotechnology and automation." Currently, GentleGen has built an international sales network and brand foundation, forming a development structure characterized by "automated production bases in China coupled with a global business footprint."